Abstract 519P
Background
The phase Ⅲ CASPIAN study established durvalumab (D) plus etoposide with cisplatin or carboplatin (EP) as first-line standard of care (1L SoC) of ES-SCLC. The multicenter, single-arm, phase Ⅲb ORIENTAL study evaluated 1L D+EP in a large, real-world-like patient (pt) cohort in China. Preliminary safety and efficacy results were consistent with CASPIAN. Here we report final results and subgroup analysis.
Methods
Treatment-naïve ES-SCLC pts ≥18 years old with ECOG PS 0–2 received D 1500 mg + EP intravenously every 3 weeks for 4–6 cycles, followed by D monotherapy every 4 weeks until progressive disease or intolerable toxicity. Primary endpoints were immune-mediated adverse events (imAEs) and grade ≥3 AEs. Secondary endpoints included OS, PFS, and tumor response.
Results
166 pts from 32 sites were enrolled by Aug 2021 and 165 received study treatment (median [m] age 65 years; 140 [84.8%] male). At baseline, 6 (3.6%) were ECOG PS 2, 155 (93.9%) were stage Ⅳ, 21 (12.7%) had brain metastases, and 44 (26.7%) had liver metastases. By data cut-off (31 Mar 2023), median cycle number of D was 7 (range 1–25). 92 (55.8%) started subsequent systemic anticancer therapy. 40 (24.2%) reported imAEs (most common [≥5%]: hyperthyroidism [6.1%] and hypothyroidism [6.1%]; grade 1/2 mostly). Grade ≥3 AEs occurred in 82 (49.7%) pts and led to treatment interruption in 24 (14.5%). mOS was 14.8 months (mo) (m follow-up [mFU] 20.5 mo). 118 (71.5%) pts received D maintenance, with mOS of 16.6 mo. 85 (51.5%) pts received >4 EP cycles, with mOS of 17.4 mo (Table). mPFS was 6.3 mo (mFU 8.6 mo). ORR was 76.4%, with 3 (1.8%) complete responses (RECIST 1.1). Table: 519P
N=165 | 95% CI | ||
Any-cause AEs, n (%) | 161 (97.6) | ||
Grade ≥3 AEs, n (%) | 82 (49.7) | ||
imAEs, n (%) | 40 (24.2) | ||
Grade ≥3 imAEs, n (%) | 11 (6.7) | ||
mOS, mo | 14.8 | 13.2–16.0 | |
12-mo OS, % | 60.8 | 52.8–67.9 | |
24-mo OS, % | 26.2 | 17.5–35.6 | |
mPFS, mo | 6.3 | 5.6–6.5 | |
12-mo PFS, % | 17.6 | 12.0–24.1 | |
ORR, % | 76.4 | 69.1–82.6 | |
DCR, % | 89.1 | 83.3–93.4 | |
mDoR, mo | 5.1 | 4.7–5.7 | |
Subgroup analysis | n | mOS, mo | 95% CI |
Received D maintenance | 118 | 16.6 | 15.1–18.8 |
ECOG PS | |||
0–1 | 159 | 15.1 | 13.3–16.1 |
2 | 6 | 9.2 | 6.4–Not Available |
Number of EP cycles | |||
≤4 | 80 | 12.7 | 9.4–15.1 |
>4 | 85 | 17.4 | 14.0–21.7 |
First-line platinum | |||
Cisplatin | 17 | 11.1 | 6.5–18.8 |
Carboplatin | 148 | 15.2 | 13.3–16.6 |
Brain metastases | |||
With | 21 | 11.1 | 8.5–14.3 |
Without | 144 | 15.3 | 13.3–17.4 |
Liver metastases | |||
With | 44 | 9.6 | 6.5–13.2 |
Without | 121 | 16.1 | 14.3–18.2 |
Conclusions
Final results of ORIENTAL showed in the largest to date, real-world-like Chinese ES-SCLC cohort that D+EP was effective and well tolerated, further supporting D+EP as 1L SoC in China.
Clinical trial identification
NCT04449861.
Editorial acknowledgement
Medical writing support for the development of the abstract, under the input and direction of the authors, was provided by Xiaowei Ning and Bo Lyu from Costello Medical Singapore and funded by AstraZeneca China.
Legal entity responsible for the study
AstraZeneca China.
Funding
AstraZeneca China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract